ChemGenex research backs Ceflatonin for acute myeloid leukemia

By Jennifer Chiou

New York, March 22 - ChemGenex Pharmaceuticals Ltd. announced it published pre-clinical research supporting the expansion of its clinical development of Ceflatonin to include treatment of acute myeloid leukemia patients.

The drug has programs for chronic myeloid leukemia and myelodysplastic syndrome.

The research details the cellular mode of action of homoharringtonine, or sHHT, in acute myeloid leukemia patient cells, including that Ceflatonin induced apoptosis or cell death in acute myeloid leukemia patient cells grown in culture.

"We have recently reported positive phase 2 data for Ceflatonin treating CML [chronic myeloid leukemia] and have ongoing and planned clinical programs in MDS [myelodysplastic syndrome] and AML [acute myeloid leukemia]," ChemGenex chief executive officer and managing director Greg Collier said in a news release.

"There is significant unmet medical need across a range of leukemias globally and we believe that Ceflatonin has the potential to meet these needs for many patients."

The Melbourne, Australia, pharmaceutical company develops therapeutics in the areas of oncology, diabetes, obesity and depression.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.